Novartis Continue To Battle Roche To Create The Number One Lung Cancer Drug

Novartis Vs Roche

The Disease Diagnosis Innovation is becoming a battle to produce the leading drug for lung cancer is heating up.On one side is Zykadia from Novartis. On the other is a product called Alecensa from Roche, their current rival. Both healthcare companies already have the approval they need to be used as a second-line treatment option when Xalkori is not an option. Now the battle is on to become the number one option.

Novartis Feel That They Should Be On Top After Recent Trials And Support

 Innovation In Disease Diagnosis

Novartis is …

Continue Reading